Cytek Biosciences (CTKB) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Cytek Biosciences

NasdaqGS•Healthcare•Medical Devices

$4.700.00(0.00%)Market closed

Market Cap

$596.81M

P/S

2.9x

P/B

1.9x

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

How this company scores

AverageMetricSide Score: 44/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (4/25).

Profitability11/25

Growth14/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Long cash runwayInterest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 555.0x5y range 555.0x – 1693.4x

P/S · 2.9x5y range 2.2x – 10.7x

Currently below its 18-quarter median.

P/B · 1.9x5y range 1.1x – 5.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $596.81M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $206.71M
Q. Revenue: $48.14M
TTM EBITDA: $-36.98M
TTM Op. Income: $-44.65M
Q. Op. Income: $-11.40M
TTM Net Income: $-80.58M
Q. Net Income: $-12.16M
EPS: $-0.09
Shares Out.: $129.46M

$206.71M in TTM revenue grew 5.4% YoY, reaching $48.14M last quarter. TTM EBITDA of $-36.98M and TTM operating income of $-44.65M show growth is flowing through to the bottom line. However, net income is negative at $80.58M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 58.9%
EBITDA Margin: -21.4%
Op. Margin: -23.7%
Net Margin: -25.3%

Op. margin of -23.7% is down 0.4% YoY — costs are rising relative to revenue. Net margin at -25.3% and gross margin of 58.9% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 2% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.9x
P/B Ratio: 1.9x

P/S of 2.9x and P/B of 1.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $446.93M
Cash: $73.85M
Long-Term Debt: N/A
Book Value: $321.95M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.37M
TTM Free Cash Flow: $-12.08M
FCF Margin: -5.8%
FCF / Net Income: 0.1

TTM FCF of $-12.08M on $1.37M in operating cash flow. The FCF / Net Income ratio of 0.1x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 211% — an improving trend.